Nortriptyline – Kodiac biolabs

Plain-language summaryIntrigue 56 / 100

Nortriptyline (Pamelor, Aventyl) is the active leftover of amitriptyline, sold separately after FDA approval in 1964. The body strips one methyl group off amitriptyline to produce nortriptyline, and that small change shifts the drug toward blocking the norepinephrine pump preferentially with much less serotonin activity. It also drops the muscarinic and antihistamine load somewhat, which makes it more tolerable than the parent compound. Among older tricyclics it has the cleanest defined therapeutic blood-level window (50 to 150 ng/mL), which means clinicians can dose it precisely with a blood test rather than guessing. Used for depression, neuropathic pain, and migraine prevention. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

39/100

A well-characterized legacy TCA with real bench utility but minimal novelty and largely superseded clinical standing

Look, nortriptyline is what happens when pharmacology matures past a compound. Approved in 1964, it’s the N-desmethyl metabolite of amitriptyline, and that metabolic parentage is itself telling: the original compound was already considered a workhorse before nortriptyline entered independent clinical use. The mechanism is completely mapped. NET Ki around 4 nM, SERT closer to 18 nM, meaningful H1 antagonism, reduced but real muscarinic load. Every branch of that receptor profile has been studied to exhaustion across multiple decades in multiple labs. Thats not a criticism of the compound’s history; it just means a serious investigator isn’t going to find mechanistic surprises here.

Where nortriptyline does outperform amitriptyline is tolerability, specifically the lower anticholinergic burden (M1 Ki roughly 150 nM versus 18 nM for the parent), and that difference is real and clinically meaningful. But the comparison set matters. Against modern SNRIs like duloxetine for neuropathic pain, or against varenicline for smoking cessation, nortriptyline is second-line or lower across nearly every approved and off-label indication. It hasn’t defined its class; it refined a position within a class that’s mostly been vacated by newer chemotypes.

The evidence quality is actually one of the stronger aspects of the profile. Sixty years of clinical data, well-established therapeutic plasma monitoring windows (50 to 150 ng/mL), CYP2D6 metabolism characterized in detail, interaction profiles documented across hundreds of polypharmacy combinations. That depth of evidence is genuinely useful for some research designs and shouldn’t be dismissed. The translational signal is also real: nortriptyline works for depression, works for neuropathic pain, and the smoking cessation signal is well-replicated even if the effect size is modest against better alternatives.

What we think is most honest here: nortriptyline retains specific research value as the canonical secondary amine TCA reference compound. If you’re studying NET-preferring reuptake inhibition in a TCA scaffold, or comparing anticholinergic burden across tricyclic structures, it’s the right tool. That use case is narrow but legitimate, and it’s what keeps the bench_value score from bottoming out. But as an object of primary research interest, honestly, there isn’t much frontier left. The compound doesn’t unlock new biology, the indication space is saturated with better options, and the mechanism has no unexplored angles that the literature hasn’t already addressed multiple times. Score accordingly.

Novelty: 18
Mechanism promise: 22
In-category differentiation: 28
Evidence quality: 68
Translational signal: 62
Research bench value: 55

Rationale Nortriptyline scores low on novelty and mechanism because it is a 60-year-old TCA with a thoroughly mapped pharmacology; it earns back points on evidence quality and translational signal given decades of real clinical use, and modest bench_value credit as the canonical secondary amine TCA reference compound in mechanistic studies.

Tricyclic antidepressant (secondary amine)

The N-desmethyl active metabolite of amitriptyline; a NET-preferring TCA with a more favorable side effect profile.

Abstract

Nortriptyline (3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methylpropan-1-amine; CAS 72-69-5; molecular formula C19H21N; molecular weight 263.38) is the N-desmethyl active metabolite of amitriptyline, marketed independently as Pamelor and Aventyl after FDA approval in 1964. As a secondary amine TCA, the compound exhibits substantially greater NET selectivity than amitriptyline (NET Ki approximately 4 nM, SERT Ki approximately 18 nM) and reduced muscarinic antagonism (M1 Ki approximately 150 nM versus 18 nM for amitriptyline), producing a cleaner side effect profile. H1 antagonism remains significant (Ki approximately 10 nM) and contributes to residual sedation, but the anticholinergic burden is meaningfully lower. Plasma half-life is 18 to 35 hours; metabolism is via CYP2D6 (primary). Approved for major depressive disorder; widely used at low dose (10 to 75 mg) for chronic pain, neuropathy, and as a smoking cessation aid (off-label). Therapeutic plasma concentrations are well-defined (50 to 150 ng/mL) and routinely monitored, distinguishing nortriptyline from most modern antidepressants. Used as the canonical secondary amine TCA in mechanism studies.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-217Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.